PDF file: 441-2094_Biodistribution_studies.pdf
OPQ ID: 441-2094
Session: 441
Question number: Q-2094
Sessional paper: Q-2094
Title: Biodistribution studies
Short description: 
Topic: vaccines
Identified concern: 
Keywords: 
Agencies: HC, PHAC, NACI
Date asked: 2023-12-11
Date tabled: 
Submitted by: Mr. Carrie (Oshawa)
Reply by: Minister of Health
Responded by: the Honourable Mark Holland
Pages: 4
Status: not processed
Alert: grey
Questions asked: 3
Questions answered: 3
Percent responded: 100%
Referenced sources: Canada.ca, COVID-19 vaccines and treatments portal
Referenced links: https://bit.ly/3E5bytJ
Official link: https://www.google.com/search?q=Q-2094+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-2094_Biodistribution_studies.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-2094.txt
Original filename: Q-2094_HC, Biodistribution studies.pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-2094_HC, Biodistribution studies.pdf
Machine extracted at: 2026-06-30 12:58:25

References / links:
- https://bit.ly/3E5bytJ.Part
- Canada.ca
- COVID-19 vaccines and treatments portal

Machine notes:
(none)

Question text preview:
With regard to Health Canada’s (HC) authorization of the COVID-19 vaccines: did any of the manufacturers provide biodistribution studies to
Canada’s regulatory agencies, departments, or other government entities, and, if so, (i) when were the studies provided, (ii) based on the biodistribution studies, where in the body was DNA or modified RNA, lipid nanoparticles and spike protein found, (iii) what percentage of the dose remained at the injection site at acute timepoints, (iv) for what period of time did this material remain in the organs or tissues of the body, including blood and bone marrow, (v) what was the period of time that biodistribution studies tracked this material in animal subjects, and was this time sufficient to confirm elimination of DNA, modified RNA, lipid nanoparticles and spike proteins, (vi) how many doses were evaluated in the biodistribution studies and did the researchers report any ill effects on the animals at any of the doses that were studied,
(vii) were samples collected to evaluate the potential for shedding from the body, including in breast milk, (viii) if the answer to (vii) is affirmative, was shedding found in the breast milk, (ix) if the answer to (vii) is negative, why was it not required, (x) when did HC, the Public
Health Agency of Canada, or the National Advisory Committee inform the Canadian public and the medical community where and for how long these products remain in the body?